Literature DB >> 15556937

Chromatin-dependent E1A activity modulates NF-kappaB RelA-mediated repression of glucocorticoid receptor-dependent transcription.

Barbara A Burkhart1, Pratibha B Hebbar, Kevin W Trotter, Trevor K Archer.   

Abstract

The role of chromatin-dependent regulatory mechanisms in the repression of glucocorticoid-dependent transcription from the murine mammary tumor virus (MMTV) promoter by p65 and E1A was investigated by using chromatin and transiently transfected reporters. The p65 RelA subunit of NF-kappaB represses MMTV expression on either transient or integrated reporters. In contrast, the viral oncoprotein E1A represses a transient but not an integrated MMTV. E1A repression is attenuated by chromatin, suggesting p65 but not E1A manipulates chromatin appropriately to inhibit the GR. Coexpression of p65 and E1A additively represses the transient MMTV but restores the transcriptional activation of the chromatin MMTV in response to glucocorticoids. This indicates that E1A has a dominant chromatin-dependent activity that attenuates repression by p65. E1A, p65, and GR bind the MMTV promoter, and chromatin remodeling enhances binding on both repressed and activated promoters. In addition, p65 requires Brg for repression of the integrated MMTV. This suggests that neither p65 repression nor E1A attenuation of repression results from an inhibition of remodeling that prevents transcription factor binding. Furthermore, p300/CBP is also required for both repression and attenuation by p65 and E1A. E1A and p65 mutants that do not bind p300/CBP are inactive, indicative of a requirement for p300/CBP-dependent complex formation for both repression and attenuation with chromatin. These data suggest that both the p65-dependent repression and the E1A-mediated attenuation of repression require the Brg1-dependent chromatin remodeling function and p300/CBP-dependent complex formation at a promoter assembled within chromatin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15556937     DOI: 10.1074/jbc.M411147200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

2.  BRG1 chromatin remodeling activity is required for efficient chromatin binding by repressor element 1-silencing transcription factor (REST) and facilitates REST-mediated repression.

Authors:  Lezanne Ooi; Nikolai D Belyaev; Katsuhide Miyake; Ian C Wood; Noel J Buckley
Journal:  J Biol Chem       Date:  2006-10-04       Impact factor: 5.157

3.  CCN2 suppresses catabolic effects of interleukin-1β through α5β1 and αVβ3 integrins in nucleus pulposus cells: implications in intervertebral disc degeneration.

Authors:  Cassie M Tran; Zachary R Schoepflin; Dessislava Z Markova; Christopher K Kepler; D Greg Anderson; Irving M Shapiro; Makarand V Risbud
Journal:  J Biol Chem       Date:  2014-01-24       Impact factor: 5.157

4.  Long-term low level glucocorticoid exposure induces persistent repression in chromatin.

Authors:  Barbara A Burkhart; Melissa L Ivey; Trevor K Archer
Journal:  Mol Cell Endocrinol       Date:  2008-10-19       Impact factor: 4.102

5.  Structural characterization of interactions between transactivation domain 1 of the p65 subunit of NF-κB and transcription regulatory factors.

Authors:  Lauriane Lecoq; Luca Raiola; Philippe R Chabot; Normand Cyr; Geneviève Arseneault; Pascale Legault; James G Omichinski
Journal:  Nucleic Acids Res       Date:  2017-05-19       Impact factor: 16.971

6.  Rhythmic PER abundance defines a critical nodal point for negative feedback within the circadian clock mechanism.

Authors:  Rongmin Chen; Aaron Schirmer; Yongjin Lee; Hyeongmin Lee; Vivek Kumar; Seung-Hee Yoo; Joseph S Takahashi; Choogon Lee
Journal:  Mol Cell       Date:  2009-11-13       Impact factor: 17.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.